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Abstract
Ectopic lymphoid-like structures (ELS) are often observed in cancer, yet their function is obscure. 
Although ELSs signify good prognosis in certain malignancies, we found that hepatic ELSs 
indicate poor prognosis in hepatocellular carcinoma (HCC). We studied an HCC mouse model, 
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displaying abundant ELSs and found that they constitute immunopathological microniches, 
wherein progenitor malignant hepatocytes appear and thrive in a complex cellular and cytokine 
milieu until gaining self-sufficiency. Progenitor egression and tumor formation is associated with 
autocrine production of cytokines previously provided by the niche. ELSs develop upon 
cooperation between the innate and adaptive immune system which is facilitated by NF-κB 
activation and abolished by T cell depletion. These aberrant immune foci could be new targets for 
cancer therapy.
A central feature of tissue inflammation is the interaction between resident cells and immune 
cells. Cellular infiltration usually entails a diffuse influx of immune cells, scattered 
throughout the inflamed tissue. However, infiltrating leukocytes often form simple lymphoid 
aggregates or even more complex structures that histologically resemble lymphoid 
organs1, 2. These structures direct various B and T cell responses, possess organization of an 
appropriate microarchitecture and are referred to as ectopic lymphoid-like structures (ELS). 
ELSs often develop at sites of chronic inflammation where they influence the course of 
many diseases including distinct autoimmune, cardiovascular, metabolic and 
neurodegenerative diseases2. Although the presence of ELSs within inflamed tissues has 
been linked to both protective and deleterious outcomes in patients, the mechanisms 
governing ectopic lymphoid neogenesis in human pathology remain poorly defined. In 
cancer, for example, solid tumors such as colorectal, lung, breast and skin carcinomas, the 
presence of tumor-associated ELSs correlates with a better prognosis3, 4, 5, 6. It is believed 
that ELSs may coordinate endogenous antitumor immune responses that improve patient 
survival1, 5, 7. A role for ELSs in the premalignant phase of tumor growth has not been 
explored so far.
Hepatocellular carcinoma (HCC) is a major health problem, being the second leading cause 
of cancer-related deaths worldwide8. In most cases, human HCC is driven by chronic liver 
inflammation due to chronic viral hepatitis and non-alcoholic steatohepatitis (NASH)9, 10. 
Formation of hepatic ELSs is a prominent pathological hallmark of chronic viral 
infection11, 12, yet a functional role for these immune follicles in HCC pathogenesis has not 
been suggested or explored. Here we report that ELSs are associated with a poor prognosis 
in human HCC. Furthermore, we present a mouse model displaying abundant hepatic ELSs 
prior to the appearance of frank HCC nodules, for investigating the pathophysiological 
relationship between ELSs and tumor development. ELSs form cytokine rich microniches in 
which HCC progenitors thrive before gaining independence and moving out of the niches to 
from full blown HCCs. Interrupting ELS function abrogates HCC formation.
RESULTS
ELSs depend on NF-κB and signify poor prognosis in human HCC
To assess the relationship between hepatic ELS prevalence and prognosis in human HCC, 
we quantified the numbers of ELSs in the non-neoplastic liver parenchyma in a well-
characterized cohort of 82 patients having undergone HCC resection, for which we had 
obtained clinical data, histological slides and gene expression data of the liver 
parenchyma13. ELS prevalence was histologically assessed in 66 cases (the subset of cases 
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with H&E-stained slides), using a published quantification scale14 (Fig. 1a and 
Supplementary Fig. 1a). This analysis revealed that in contrast to colon, breast, lung and 
skin cancers3, 4, 5, 6, a high histological ELS score was associated with increased risk for late 
recurrence and a trend towards decreased overall survival after HCC resection 
(Supplementary Fig. 1b-d).
A 12-gene signature was shown to accurately assess the presence of ELSs in human tissues1. 
Using expression data available for these patients, we found a strong correlation between the 
histological ELS score and the 12 gene ELS signature (Fig. 1a, p<0.001), confirming its 
utility in the liver and enabling us to expand the analysis to include all 82 patients with 
transcriptome profiles. Fifteen out of 82 patients (18%) presented the ELS gene signature in 
the liver parenchyma (Fig. 1a), which was significantly associated with poor survival of 
HCC patients after curative surgical resection (Fig. 1b, p=0.01) and increased risk of late, 
but not early recurrence (Fig. 1c and Supplementary Fig. 1e; p=0.03 and p=0.34, 
respectively). Of note, multivariable analysis showed that the ELS gene signature is an 
independent prognostic factor from the 186-gene prognostic - HCC risk gene signature 
previously identified in this cohort13, as well as the clinical prognostic staging system (Fig. 
1d,e). Late recurrence, occurring 2 years after surgery, is considered to represent de novo 
carcinogenesis from the inflamed liver, while early recurrence occurring within 2 years of 
surgery results from dissemination of primary tumor cells15. Collectively, our clinical cohort 
analysis suggested that ELSs are associated with de novo HCC development in chronically 
inflamed and fibrotic or cirrhotic human livers.
The mechanisms underlying ELS formation in general and in cancer in particular are mostly 
obscure2, 16. To identify signaling pathways that could initiate or facilitate ELS development 
in HCC, we performed gene set enrichment analysis (GSEA) comparing gene expression in 
the liver parenchyma between patients with high vs. low ELS gene signatures. This analysis 
highlighted the interferon response and NF-κB signaling as top candidates (Supplementary 
Table 1). Further analysis of the correlation between activation of NF-κB signaling and 
hepatic ELSs using 3 different published NF-κB signatures confirmed the association for 
NF-κB (Fig. 1f and Supplementary Fig. 1f). These findings suggest that activation of the I 
kappa B kinase (IKK)-NF-κB signaling pathway could be an important mediator of hepatic 
ELS generation.
Persistent IKK activation in hepatocytes induces ELSs
In order to examine the contribution of NF-κB signaling to generation of ELS and HCC, we 
developed an animal model. To activate the IKK-NF-κB signaling pathway in hepatocytes, 
we bred R26StopFLIkk2ca mice17 with Albumin-cre (Alb-cre) mice18. The resulting 
IKKβ(EE)Hep mice express constitutively active IKKβ(EE) in hepatocytes (Fig. 2a) and 
show nuclear NF-κB and transcriptional activity comparable in their amounts to Mdr2−/− 
(also known as Abcb4−/−) mice, a model of chronic hepatitis19, but lower than TNF treated 
mice (Supplementary Fig. 2a-d), suggesting that IKKβ(EE)Hep mice display a level of innate 
immune activity which is similar to that present in common forms of chronic hepatitis. The 
livers of 3 month old IKKβ(EE)Hep mice lacked overt histopathology (Supplementary Fig. 
2e). At 7 months IKKβ(EE)Hep mice revealed mild increases in liver macrophages, liver 
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damage markers and hepatocyte proliferation (Supplementary Fig. 2f-k). Importantly, 
multiple ELSs were apparent in livers of 7 month old IKKβ(EE)Hep mice, gradually growing 
in both size and number (Fig. 2b,c). Immunohistochemical staining revealed that ELSs were 
composed of T and B lymphocytes, neutrophils (located in the ELS periphery), NK cells, 
macrophages, T regulatory (Treg) cells, follicular dendritic cells and contained high 
endothelial venules, confirming that these were bona fide ELSs (Fig. 2d). We next analyzed 
ELSs present in the parenchyma of human livers with hepatitis (that were resected for HCC) 
and compared their immune cell composition to that of hepatic ELSs in IKKβ(EE)Hep mice. 
Histological analysis revealed that ELSs in IKKβ(EE)Hep mice were highly similar to their 
human counterparts (Fig. 2d). Flow cytometry of single cell suspensions of mouse ELSs 
confirmed the immunohistochemical analysis (Fig. 2e and Supplementary Fig. 2l,m). B and 
T lymphocyte compartmentalization, another characteristic feature of ELSs, was also 
observed in ELSs in IKKβ(EE)Hep mice and human hepatitis (Supplementary Fig. 2n). 
Furthermore, the ELS gene signature was significantly upregulated in liver parenchymas of 
IKKβ(EE)Hep mice compared to control Alb-cre mice (Supplementary Fig. 2o and 
Supplementary Table 2). Thus, persistent IKK activation in hepatocytes could be a key 
mediator of hepatic ELS formation in human hepatitis.
Hepatic ELSs herald aggressive HCCs in IKKβ(EE)Hep mice
At 20 months of age, 100% of IKKβ(EE)Hep mice developed HCC compared to 8% of 
control Alb-cre mice (Fig. 3a-c, p<0.0001). Histological analysis revealed that 
approximately half of IKKβ(EE)Hep tumors were well differentiated HCCs (WD-HCC); the 
remaining tumors were mixed cholangio-hepatocellular carcinomas (HCC-CCC, Fig. 3d), 
recognized by the presence of malignant glandular structures. Immunostaining for the HCC 
markers A6 and glutamine synthetase (GS), the proliferation marker Ki-67 and the matrix 
associated collagen IV (whose expression is downregulated in HCC), and the presence of 
metastases to lymph nodes and lungs confirmed that these were aggressive malignant HCCs 
(Supplementary Fig. 3a-c). Notably, mice harboring a single allele of IKKβ(EE) showed 
decreased ELS number and size at 14 months (Supplementary Fig. 3d,e) followed by a 
similar decrease in HCC load at 20 months, when compared to mice harboring two such 
alleles (Supplementary Fig. 3f,g), underscoring an NF-κB dose-dependent ELS phenotype 
and an association between ELSs and HCC, respectively.
We also generated transgenic mice in which IKKβ(EE) is driven by the Albumin promoter 
[Alb-IKKβ(EE) mice]. Of note, these mice also displayed ELSs and mild inflammation, 
followed with development of HCC (Supplementary Fig. 3h-j), corroborating the 
hepatocarcinogenic effect of constitutive IKKβ(EE) expression in hepatocytes in a distinct 
mouse model. Treating IKKβ(EE)Hep mice with the hepatic carcinogen diethylnitrosamine 
(DEN) accelerated the appearance of ELSs (now appearing at 3 months), and HCCs 
(appearing at 9 months), without significantly altering their histological and molecular 
characteristics (Supplementary Fig. 3k-r).
Analysis of expression of a 16 gene set for assessing HCC aggressiveness20, revealed that 
HCCs from DEN-treated wild-type mice tended to cluster with wild-type livers, while HCCs 
from IKKβ(EE)Hep mice clustered with aggressive HCCs from transgenic mice 
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overexpressing Myc in hepatocytes together with germline deletion of TP53 (Myc-TP53−/−, 
Fig. 3e, 7 out of 10 compared with 2 out of 20, p=0.002, Fisher’s exact test). Tumors 
displaying the HCC-CCC morphology, which were only detected in the IKKβ(EE)Hep mice 
and not found in control DEN-treated ones, clustered with the more aggressive group (Fig. 
3e). Of note, we could not detect a difference in the gene expression pattern between 
spontaneous and DEN induced HCCs in IKKβ(EE)Hep mice. Array comparative genomic 
hybridization (CGH) analyses of HCCs from DEN-treated Alb-cre control (n=12), DEN-
treated IKKβ(EE)Hep mice (n=11) and 20-months old IKKβ(EE)Hep mice (n=13) revealed 
chromosomal aberrations in all HCC samples, confirming their neoplastic nature. Data are 
stored and available from ArrayExpress (https://www.ebi.ac.uk/arrayexpress/) accession 
number E-MTAB-3848. Mixed HCC-CCC tumors were more complex than WD-HCC 
(Supplementary Fig. 3s). To validate the array CGH analysis, we prepared digital PCR 
probes directed at two genes, Rgs2 and Gab2, targeting the two most common genomic 
amplifications. This analysis revealed a 90% concordance with results of the array CGH 
analysis. In addition, analysis of 13 additional IKKβ(EE)Hep HCCs revealed the presence of 
amplification of Rgs2 gene copy number in 38% and amplification of Gab2 gene copy 
number in 30% of the HCCs tested (Supplementary Fig. 3t). Taken together, these data 
confirmed that IKKβ(EE)Hep mice develop aggressive HCCs with a 100% penetrance.
HCC progenitors first appear inside ELSs and later egress
Careful histological analysis revealed that the earliest malignant hepatocytes (noted at 3 and 
7 months in DEN-treated and untreated IKKβ(EE)Hep mice, respectively), appeared first 
within newly-formed ELSs. These malignant hepatocytes were double positive for GFP 
(expressed from the hepatocyte specific IKKβ(EE) transgene) and E-cadherin, confirming 
their hepatocyte origin and epithelial phenotype (Fig. 4a), and expressed multiple markers of 
HCC progenitors including A6, GP73 (GOLPH2), Sox9, CD44v621 and CK19 (Fig. 4b). At 
these earliest time points, HCC progenitors were largely found in ELSs and not elsewhere in 
the liver parenchyma (Supplementary Fig. 4a-c). GFP expression proved that these cells 
were derived from hepatocytes expressing the Alb-cre transgene (Supplementary Fig. 4d). 
These small clusters gradually grew, initially within ELSs and later on, migrating out to 
form visible tumors (Fig. 4c and Supplementary Fig. 4e). This histological sequence, of 
small groups of cells first appearing within ELSs, followed with gradual coalescence of 
groups of cells within the follicle boundary, which finally grew out into full-blown HCCs, 
was consistently seen in all IKKβ(EE)Hep mice of appropriate age in both spontaneous and 
DEN-treated groups (Supplementary Fig. 4f,g). To unequivocally prove the neoplastic nature 
of the epithelial cells that grew within the ELSs, we used laser capture micro-dissection to 
collect enriched populations of these cells. Indeed, 3 out of 11 lesions harbored 
amplification of Rgs2 and 1 out of 11 harbored amplification of Gab2 (Supplementary Fig. 
4h), corroborating the neoplastic nature of these lesions and providing a genetic link 
between the malignant cells that were thriving within the ELSs and HCCs of IKKβ(EE)Hep 
mice.
Of note, several months after the first appearance of ELSs, we consistently observed clusters 
of malignant hepatocytes budding from the ELSs (Supplementary Fig. 4i). These clusters 
were either in continuity with or slightly separated from the intra-ELS malignant cells. To 
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better visualize the egression of clusters of malignant cells we co-immunostained serial 
sections with antibodies against CD44v6 (a marker for HCC progenitor cells21) and B220 
and generated 3 dimensional reconstructions of ELSs. The resulting 3 dimensional 
representations clearly showed clusters of malignant cells budding out of ELSs (Fig. 4d and 
Supplementary video 1).
Although the IKKβ(EE) transgene is expressed throughout the parenchyma, ELSs are focal, 
suggesting that additional factors trigger ELS formation. Finding that ELS appearance was 
accelerated by DEN administration (Supplementary Fig. 3l,m) suggests that tissue damage 
could be of relevance, either by focal enhancement of hepatocyte NF-κB activation, or by 
triggering another cooperating pro-inflammatory pathway. To test this possibility we 
assessed the microanatomical localization of ELSs with respect to different liver zones. DEN 
is converted to its active metabolite in pericentral hepatocytes. Thus, if genotoxic stress is 
directly involved in formation of ELSs, the latter will be localized to pericentral regions. 
Immunostaining with GS (a marker of pericentral hepatocytes) revealed that ELSs were 
evenly distributed in the 3 liver zones in untreated IKKβ(EE)Hep mice; however, in DEN 
treated IKKβ(EE)Hep mice ELSs were almost entirely limited to the pericentral zone (Fig. 4e 
and Supplementary Fig. 4j, p<0.0001), suggesting a causal relationship between genotoxic 
stress and ELS formation.
To find out if HCC progenitors are also found in ELSs of human patients, we analyzed liver 
parenchyma from human livers resected for HCC. Triple immunofluorescence with 
antibodies against the human HCC markers HSP70 and SOX9 together with CK19 (which 
marks reactive ductular cells), revealed the presence of cells with HCC progenitor features 
within the human ELSs (Fig. 4f), attesting to a common ELS-related pathogenic mechanism 
in human HCC and the mouse model.
Depletion of ELSs markedly attenuates murine HCC
The adaptive immune system is commonly considered a defense mechanism against cancer 
progression; accordingly human HCCs showing marked lymphocytic infiltration were found 
to have a better prognosis22 and Rag1−/− mice, lacking an adaptive immune system, were 
shown to have more HCCs after DEN treatment23. Yet, despite its defense function, immune 
activation can result in various pathologies including cancer24, 25.
To test the functional role of ELSs in hepatocarcinogenesis, we bred IKKβ(EE)Hep mice 
with Rag1−/− mice which completely lack B and T cells. Consistent with a previous report23, 
there was a small increase in HCC numbers in DEN treated Rag1−/− mice (Fig. 5a-d). As 
expected, Rag1 deletion in IKKβ(EE)Hep mice resulted in complete elimination of ELSs. 
However, in stark contrast with its pro-tumorigenic effect in Rag1−/− mice, loss of the 
adaptive immune system in IKKβ(EE)Hep -Rag1−/− mice dramatically attenuated 
hepatocarcinogenesis; most, if not all, of the pro-tumorigenic effect of the IKKβ(EE) 
transgene was lost in the absence of Rag1 (Fig. 5a-d). Tumors that do develop in Rag1−/− 
IKKβ(EE)Hep mice were exclusively typical, WD-HCC and were negative for most HCC 
progenitors markers (Fig. 5e-g). Comparing proliferation, apoptosis and RelA (p65) nuclear 
accumulation between the HCCs in IKKβ(EE)Hep -Rag1−/− to well differentiated HCCs of 
IKKβ(EE)Hep mice did not reveal significant differences (Supplementary Fig. 5a-f), arguing 
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against a cell-autonomous effect of Rag1 deficiency on HCC growth. Taken together these 
data suggest that generation of a focal immune microniche is dependent on a functional 
adaptive immune system and that the immune microniche promotes HCC.
To test whether ablation of ELS function after induction of tumors by DEN could still affect 
HCC formation in IKKβ(EE)Hep mice, we administered anti-Thy1.2 antibody, to ablate T 
cells and potentially also innate lymphoid cells and NK cells which were also reported to 
respond to anti-Thy1.2 treatment, to mice between 18 to 30 weeks of age. Control mice 
received an isotype matched control antibody (Supplementary Fig. 6a). Immunostaining 
livers for CD3 confirmed almost complete T cell ablation (Fig. 6a). Indeed, anti-Thy1.2 
treatment restricted ELS development (Fig. 6b), and markedly reduced HCC multiplicity and 
burden in IKKβ(EE)Hep mice (Fig. 6c-e and Supplementary Fig. 6b-d). Thus, the adaptive 
immune system plays a strong pro-tumorigenic effect in IKKβ(EE)Hep mice, which takes 
place after acquisition of the initiating tumor mutations.
ELSs express high amounts of growth promoting cytokines
We hypothesized that cytokines secreted by adaptive immune cells possibly present at high 
concentrations within ELSs, could underlie their tumor-promoting effects. To identify pro-
tumorigenic signals operative within ELSs, we measured expression of multiple cytokines in 
liver parenchyma, ELSs and HCCs from IKKβ(EE)Hep mice and in human chronic viral 
hepatitis. Among others, Lymphotoxin (LT) family members, in particular LTβ and LIGHT 
(also known as TNFSF14), and their downstream effectors, CCL17 and CCL20, were 
prominently overexpressed in human and mouse samples, along with signs of LT-driven non-
canonical NF-κB pathway activation (Fig. 7a,b and Supplementary Fig. 7a-d). LTβ is also 
expressed in ELSs of patients with chronic hepatitis (Fig. 7b,c). Moreover, we noted a 
significant correlation between CCL17 and CCL20 mRNA expression and that of LTβ in 
both human and mouse samples (Supplementary Fig. e-h). This suggests that Lymphotoxin β 
receptor (LTβR) activation by LTα, LTβ and/or LIGHT could play a key role in ELS 
assembly and pro-tumorigenic processes26, 27, 28, 29. LTβR was reported to be expressed on 
hepatocytes, whereas LTα and LTβ are normally expressed in lymphocytes30. Indeed, 
mRNA in situ hybridization revealed that LTβ mRNA was expressed in immune, but not 
epithelial cells in small ELSs (Fig. 7d and Supplementary Fig. 7i). To identify the specific 
cell types which express LTβ, we used flow sorting of single cell suspensions from ELSs. 
This analysis revealed the LTβ mRNA was expressed by both T and B lymphocytes, but not 
by hepatocytes (Supplementary Fig. 7j). However, in advanced large ELSs, some of the 
neoplastic hepatocytes also expressed LTβ and all full-blown HCCs always express LTβ 
mRNA by histology (Fig. 7d and Supplementary Fig. 7i). Notably, when varying degrees of 
expression were noted in malignant hepatocytes within an ELS, LTβ mRNA expression 
occurred in malignant hepatocytes at the ELS periphery, in particular within the egressing 
clusters (Fig. 7e,f and Supplementary Fig. 7k,l). This raised the hypothesis that immune 
cells within the ELSs provide paracrine LT signals to early HCC progenitors, which are later 
replaced by an autocrine signal, allowing the malignant hepatocytes to gain independence 
from the niche. This presumption could be supported by the observation that transgenic 
overexpression of LTα and β in hepatocytes was found to induce HCC26. Importantly, HCCs 
that developed in IKKβ(EE)Hep mice under anti-Thy1.2-treatment and in IKKβ(EE)Hep -
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Rag1−/− livers showed marked reduction in LTβ mRNA expression, suggesting that exposure 
of tumor progenitors at early stages to niche-derived cytokines, renders them addicted to 
these cytokines, favoring acquisition of autocrine abilities to produce the same cytokines 
(Fig 7g,h and Supplementary Fig. 7m-p).
To test this hypothesis we blocked LT cytokines using a soluble LTβR fused to a murine 
immunoglobulin Fc portion (LTβR-Ig)26. Furthermore, to denote the time point of when LT 
blockade had the most efficient biologic effect, we subjected IKKβ(EE)Hep mice to three 
treatment regimens: 3-12 weeks of age, when LTβ is expressed by ELS immune cells; 13-22 
weeks of age, when LTβ is expressed by both immune and malignant ELS cells; and 23-32 
weeks of age during which LTβ is expressed similarly to the intermediate period, yet HCCs 
are more developed (Supplementary Fig. 8a,b). Measurements of expression of multiple 
cytokines in liver parenchyma showed reduction in many of the pro-inflammatory and of the 
LT-mediated cytokines (Fig. 8a). Of note, blocking LT signaling was associated with 
reduced NF-κB activation in ELS-residing malignant hepatocytes (Supplementary Fig. 
8c,d), suggesting that LT signaling enhanced the low level of NF-κB activation induced by 
the IKKβ(EE) transgene. Remarkably, LTβR-Ig treatment in early and intermediate periods 
dramatically reduced HCC burden (Fig. 8b and Supplementary Fig. 8e,f). In contrast, LTβR-
signaling inhibition at the late period resulted in a smaller, non-significant effect on HCC 
number and tumor volume. As LT inhibition proved ineffective in reducing tumorigenesis 
beyond 23 weeks of age, we hypothesized that the major inhibitory effect of LT-blockade 
could have been in ELSs where LT is primarily provided by the lymphocytes rather than in 
an autocrine manner by niche-external tumor cells. Indeed, histological inspection of early 
tumorigenesis stages in the late treatment group revealed a marked reduction in the number 
of intra-ELS HCC progenitors, and in both multiplicity and size of clusters of egressing cells 
(Fig. 8c,d and Supplementary Fig. 8g). This was associated with reduced proliferation of 
HCC progenitor cells in ELSs upon treatment (CDC47+Sox9+ doubly-labeled cells, Fig. 8e-
g), possibly accounting for a lower number of ELS-egressing atypical hepatocytes (Fig. 
8c,d). It thus appears that paracrine LT stimulation within ELSs is a critical step in HCC 
development, amenable to anti-tumor intervention.
DISCUSSION
Our study reveals a liver tumorigenesis program wherein specialized ELSs, associated with 
chronic NF-κB activation, foster atypical hepatocytes, that eventually acquire malignant 
properties. Importantly, our study indicates that ELSs - which are commonly present in 
human livers with HCC - promote rather than counteract tumor development as was 
previously demonstrated for several tumor types3, 4, 5, 6, 7. This highlights the existence of 
contrasting roles of ELSs in cancer that may be related to the different cancer types or 
perhaps reflect alternative phenotypes of ELSs. Shortly following ELS expansion and tumor 
progenitor egression, we observe distinct tumors carrying similar chromosomal aberrations, 
indicating that the tumors originated from ELS-nested atypical hepatocytes. The pro-
tumorigenic effect of ELSs requires a competent adaptive immune system, providing 
lymphocyte-derived cytokines, supporting HCC progenitors until they are ready to egress 
out of their niches. Related hepatic ELSs are commonly found in chronic hepatitis patients 
who are at risk of developing HCC, ELSs might constitute a microniche for the population 
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of expanding HCC progenitor cells supporting cancer development. Similarly to our mouse 
models, these human follicles may form due to constitutive IKK activation by chronic 
hepatitis virus infection (e.g. HBV31, HCV32, 33). We may have therefore identified a critical 
window of immune-inflammatory action in tumor development, namely intra-niche growth 
of early tumor progenitors. The immune microniche environment appears to provide tumor 
progenitor cells with crucial survival and growth factors. Accordingly, preventing niche 
assembly or interfering with niche function significantly reduced HCC load in IKKβ(EE)Hep 
mice. ELSs are unique micro-anatomic structures which are commonly observed in multiple 
disease states, including cancer2. Specifically in the liver, ELSs are associated with chronic 
hepatitis11, 12, 34. The IKKβ(EE)Hep model provides for the first time functional information 
for ELSs, showing that they provide a unique microenvironment supporting growth of tumor 
progenitor cells. This notion is corroborated by our human studies showing a higher 
probability of late recurrence and death after HCC resection in patients with high hepatic 
ELS numbers. Of note, late recurrence, occurring 2 years after surgery, is considered to 
represent de novo carcinogenesis15.
Although our Rag1−/− experiments confirm previous studies showing that certain adaptive 
immune cells can play an anti-tumor role in hepatocarcinogenesis (i.e. in the absence of 
IKK-induced ELS formation), they reveal the dramatic pro-tumorigenic potential of adaptive 
immune cells in specific forms such as the ELS. An obvious difference between the pro- and 
anti-tumorigenic states is formation of highly structured microanatomic structures composed 
of hundreds of immune cells where the dominant effect is pro-tumorigenic. It is becoming 
clear that in lymphatic organs, three dimensional structures are key for shaping intercellular 
communication and cooperation among multiple immune cell types, frequently involving 
physical cell-cell interactions that are meticulously orchestrated to generate multiple effector 
mechanisms and bestow different phenotypes on the interacting cells35. Thus, the unique 
structure of the ELS as well as structural and composition changes over time could explain 
how the adaptive immune system turns from anti- to pro-tumorigenic. One obvious 
difference is that the compact structure of the ELS, grouping together high numbers of 
immune cells, likely suffices to generate a niche containing high concentrations of immune 
derived cytokines and growth factors providing a tumor-promoting environment.
Formation of ELSs is thought to depend on innate lymphoid cells (LTi) that are recruited to 
extranodal sites by chemoattracting cytokines2. The association between NF-κB activation 
in human livers and the 100% prevalence of ELSs in IKKβ(EE)Hep livers suggests that 
activation of hepatocyte NF-κB (known to occur in chronic hepatitis of diverse etiologies) 
plays a role in ELS formation in the liver, linking instigation of epithelial innate immunity 
and focal activation of adaptive immunity36. Although NF-κB is activated throughout the 
liver of IKKβ(EE)Hep mice, ELSs are focal, suggesting that additional cues are needed. 
Finding that ELS formation is significantly accelerated by DEN suggests that genotoxic 
stress could play a role in ELS formation. Supporting this notion is the different distribution 
of ELSs. In untreated IKKβ(EE)hep mice, ELSs are evenly distributed between liver zones, 
whereas in DEN treated mice, the ELSs are largely located in the pericentral zone where 
DEN is converted from a pro-carcinogen to a carcinogen that can attack DNA37. This joint 
activation of the NF-κB and DNA damage response pathways possibly generates a threshold 
level of cytokines that are sufficient to invoke the formation of ELSs. Of note, although a 
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previous report suggested that a persistently active IKK transgene expressed in hepatocytes 
did not lead to HCC induction38, it is plausible that either the expression level was not 
sufficiently high or that the follow up time was not long enough. Indeed, mice harboring a 
single allele of IKKβ(EE) show diminished tumor load compared with mice harboring two 
alleles, demonstrating that the level of expression of the transgene is important. Furthermore, 
we noted HCC development in two different IKK transgenic strains kept in different 
facilities.
Egression of tumor cells out of the niche where they first grew is a remarkable phenomenon 
observed in IKKβ(EE)hep mice. Seeds of cancer may germinate in an appropriate 
microenvironment, yet are capable of leaving the nursing niche and form full-blown 
malignant tumors only upon acquiring new capabilities. We speculate that acquisition of 
niche-independence is a hallmark prerequisite of solid tumors initiated within a supportive 
niche. One specific mechanism we detected in IKKβ(EE)hep mice is the acquisition of 
autocrine LT expression, but others are also very likely to take place. Recently, tumor 
progenitors were shown to respond to IL-6 from resident tissue macrophages, but later 
acquire autocrine IL-6 signaling that promotes malignant progression21. Identifying 
additional examples of immune-dependent tumor microniches, as well as their tumor 
progenitor support and egression mechanisms, might guide effective ways of arresting these 
processes for therapeutic purposes.
METHODS
Prognostic evaluation of histological ELSs, ELS gene signature, and NF-κB activation in 
liver tissues from curatively treated HCC patients
Prognostic association of the ELS gene signature was evaluated in genome-wide 
transcriptome profiles of cirrhotic liver tissues from 82 surgically-treated HCC patients 
followed for up to 15.6 years (median 7.8 years) reported in our previous study15 (NCBI 
Gene Expression Omnibus accession number GSE10140). For each patient in the cohort, 
induction of the ELS gene signature was determined by Kolmogorov-Smirnov statistic-based 
gene set enrichment assessment39 implemented in a custom analysis code written in R 
statistical language (www.r-project.org). Significance of the signature gene induction was 
determined as a prediction confidence p-value (significance threshold p<0.05) based on null 
distribution of the statistic generated by random permutation of the samples (n=1,000). 
Prognostic association of the ELS gene signature was assessed by Kaplan-Meier curves, log-
rank test, and multivariable Cox regression modeling adjusted for the 186-gene 
prognostic/HCC risk signature we previously reported and clinical prognostic staging 
(American Association for Study of Liver Diseases [AASLD] staging system40). No clinical 
variables were associated with these clinical outcomes.
Correlation between presence of ELSs and NF-κB activation was determined by a 
modulation of 3 experimentally defined NF-kB target gene signatures in HeLa cells41 and 
primary human fibroblasts and keratinocytes42 and was evaluated in the same transcriptome 
dataset of 82 HCC patients. Histological ELS features were determined in 66 out of the 82 
patients with H&E-stained slides as previously described: vague follicular aggregation 
(Agg), definite round-shaped cluster of small lymphocytes without germinal center (Fol), 
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and follicles with definite germinal centers composed of large lymphocytes with clear 
cytoplasm (GC)14. Each section was observed independently by two reviewers that were 
blinded to the patients’ data. A consensus score was reached on a multi-head microscope in 
cases of discordance. Presence of histological ELS was defined as presence of any of the 
histological ELS features in ≥50% of portal areas for each patient.
Human liver tissue
Human liver biopsy specimens were obtained from the archives of the Institute of Surgical 
Pathology, University Hospital Zurich (USZ), Switzerland and kept anonymous. The study 
protocol was approved by the ethical committee of the “GesundheitSEMirektion Kanton 
Zurich” (Ref. Nr. StV 26-2005 and KEK-ZH-Nr. 2013-0382) and was in accordance with 
the Helsinki declaration guidelines. Additional De-identified surgically resected human liver 
tissues were obtained via Mount Sinai Biorepository (IRB approval HS10-00135).
Mice, HCC induction and anti-Thy1.2 and LTβR-Ig treatments
All animal experiments were performed in accordance with the guidelines of the Hebrew 
University, University of California, San Diego (UCSD) and NIH for the use of animals for 
research. Previously described ROSA26-LSL-IKKβ(EE) mice17 were bred with Albumin 
(Alb)-Cre mice18 obtained from Jackson Laboratory (Bar Harbor, Maine, stock # 003574) to 
generate IKKβ(EE)Hep mice. Alb-cre mice served as controls for IKKβ(EE)Hep mice. Alb-
IKKβ(EE) mice were generated at the transgenic mouse facility at UCSD as follows: HA-
tagged IKKβ(EE) cDNA43 was PCR-amplified and inserted into a plasmid containing 2.3 kb 
mouse Alb gene enhancer/promoter, rabbit β-globin second intron, rabbit β-globin 
polyadenylation signal and SV40 early gene polyadenylation signal (provided by Dr. K. 
Kohno, Nara Institute of Science and Technology, Nara, Japan)44. The expression cassette 
was excised, purified, and injected into fertilized C57BL/6 oocytes to generate founder mice, 
three of which transmitted the IKKβ(EE) transgene. Rag1−/− mice were purchased from 
Jackson Laboratory (stock # 002216), and Mdr2−/− mice have been described previously19. 
All mice were of a pure C57BL/6 genetic background and were bred and maintained in 
specific pathogen-free conditions. Only male mice were used. Animals were sacrificed by a 
lethal dose of anesthesia and perfused through the left ventricle with heparinized PBS 
followed by buffered formalin.
For hepatocarcinogenesis, mice were injected intraperitoneally (i.p) with 10 mg/kg DEN 
(Sigma) at 15 days of age. Mice were observed for development of tumors at 9 months of 
age. To inhibit LTβR-signaling, a murine LTβR: immunoglobulin G1 fusion protein (LTβR-
Ig, Biogen Idec), was used. Mice were i.p injected on a weekly basis with 100 μg of LTβR-
Ig or MOPC21 (control murine-IgG1) for 10 consecutive weeks, starting either at 3 weeks of 
age (denoted early: 3-12), 13 weeks (intermediate: 13-22), or 23 weeks (late: 23-32). Mice 
were sacrificed at 33 weeks of age to evaluate HCC development (Supplementary Fig. 8a).
Anti Thy1.2 treatment: mice were injected IP every 2 days for 12 weeks with Thy1.2 
antibody (BioXCell, catalog#: BE0066) or LTF-2 antibody for the control group (BioXCell, 
catalog#: BE0090). Mice were sacrificed at the age of 6.5 months.
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Myc-TP53−/− liver tumors were kindly provided by Marie-Annick Buendia (Institut Pasteur, 
France). Briefly, woodchuck hepatitis virus (WHV)/Myc transgenic mice were mated with 
p53−/− mice to generate mice heterozygous for both the p53 mutation and the Myc 
transgene. The WHV/ Myc p53+/delta mice spontaneously developed HCC, which frequently 
acquired a deletion of the remaining p53 allele. HCCs were further genotyped. Myc-TP53−/− 
HCCs were used as reference for a highly proliferative liver cancer in the 16-gene array 
analysis.
Serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels were 
determined using Reflotron Plus analysis system (Roche).
Examination of mouse H&E sections was performed by three expert liver pathologists (A.W, 
O.P. & E.P).
Immunohistochemistry (IHC), Immunofluorescence and 3D reconstruction
Antibodies used were directed against: A6 (provided by Valentina Factor and Snorri 
Thorgeirsson, NIH, USA); B220 (BioLegend clone RA3-6B2); CD3 (Serotec clone CD3-12 
or ZYTOMED, cat# RBK024); GFP (Invitrogen cat# A-11122); F4/80 (Serotec clone 
CI:A3-1); Ly-6G (BD Pharmingen, cat# 551459); FDC-M1 (BD Pharmingen clone # FDC-
M1); Glutamine Synthetase (GS) (Abcam cat# ab16802); GP73/ GOLPH2 (Santa Cruz cat# 
sc-48011); Foxp3 (eBioscience clone FJK-16s); Ki67 (Thermo Scientific Clone SP6); 
CDC47 (MCM7) (Santa Cruz, cat# sc-56324); RelA (p65) NeoMarkers catalog #RB-1638); 
CD44 (eBioscience clone IM7); CD44(V6) (eBioscience clone 9A4); Sox9 (Santa Cruz cat# 
sc-20095); CK19 [hybridoma TROMA-III, deposited to Developmental Studies Hybridoma 
Bank (DSHB) by Kemler Rolf]; Collagen IV (Cedarlane Laboratories cat# CL50451AP); E-
cadherin (BD clone 36/E-cadherin); Cleaved Caspase 3 (Cell Signaling cat# 9661). Antigen 
retrievals for B220, GFP, Ki67,CDC47, E-cadherin, RelA, Sox9, CK19 and Cleaved Caspase 
3 were performed in 25mM citrate buffer pH 6.0; for GP73, Ly-6G, GS, Collagen IV, Foxp3, 
CD44, CD44(V6) and CD3 in EDTA buffer pH 8.0 (Invitrogen) – all by heating to 125°C 
for 3 min in decloaking chamber (Biocare Medical). Antigen retrieval for A6 and F4/80 was 
performed by incubation with 1mg/ml Pronase XXIV (Sigma). Immunofluorescence was 
performed on FFPE sections. Fluorophore conjugated secondary antibody used were 
Donkey anti-Mouse Cy5, Donkey anti-Rat Cy3 (Jackson Immunoresearch) and Alexa-Fluor 
Donkey anti-Goat 488 (life technologies). Hoechst 33342 (Invitrogen) was used as a nuclei 
marker.
Antibodies used for human sections were: CD3 (Cell Marque cat# 103A); CD15 (Biocare 
Medical, cat# CM029); CD20 (Cell Marque cat# 120R); CD23 (Novacastra Labs clone # 
1B12); CD68 (Invitrogen clone KP1); Foxp3 (eBioscience clone # 236A/E7); HSP 70 (Santa 
Cruz, cat# sc-24) and LTβ (Biogen clone B27.B2). IHC staining of human sections was 
performed with BenchMark XT system (Ventana) using Cell Conditioning 1 (CC1, Ventana) 
for pretreatment, besides Foxp3 which was stained manually using EDTA buffer pH 8.0 
(Invitrogen) for retrieval.
For quantification, stained slides were counted either manually by counting the number of 
positive cells per 10 high-power fields, or quantified with an Ariol SL-50 automated 
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scanning microscope and image-analysis system (Applied Imaging). Briefly, the frequency 
of positive cells was assessed with the appropriate module of the Ariol SL-50. For each 
sample, the percentage of positive cells or the intensity of the staining was determined in 10, 
arbitrary chosen, fields. Three dimensional reconstruction of ELSs in the liver was done 
using the μCore software (microDimensions GmbH, München, Germany) using a Mirax 
Midi Slide Scanner (Carl Zeiss microImaging GmbH, München, Germany) as described45.
Immunoblot (IB) and electrophoretic mobility shift assay (EMSA)
Antibodies used for IB: Actin (Sigma clone AC-40); FLAG (Sigma clone Anti-Flag M2); 
p100/p52 (Cell Signaling cat #4882); RelB (Milipore cat # 06-1105); Tubulin (Sigma clone 
DM-1A). To prepare whole-cell lysates, tissues were lysed by mechanical grinding in RIPA 
buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40 and 0.25% Na-
deoxycholate) containing 1× mixture of protease inhibitors (Sigma), 10mM Na3VO4, 10mM 
Na4P2O7 and 50mM NaF. Total cell lysates were separated by SDS-PAGE and assessed by 
IB analysis, using sequential probing with the indicated primary Ab and an appropriate anti-
IgG conjugated to HRP (Jackson). Immunoreactive bands were detected using ECL 
detection reagent (Pierce).
For EMSA, IRDye 700 labeled oligonucleotide (LI-COR Biosciences) corresponding to NF-
κB specific consensus sequence was used. The binding reaction was performed using 
Odyssey Infrared electro-mobility shift assay kit (LI-COR Biosciences) according to the 
manufacturer protocol. Briefly, nuclear proteins were isolated from freshly isolated liver 
tissue using Cayman Nuclear Extraction Kit (Cayman Chemical Company) and total protein 
concentration was determined with the BCA Protein Assay Kit (Thermo Scientific). 20 ng of 
total nuclear protein was mixed with the labeled NF-κB oligonucleotide and left to bind for 
30 minutes in the dark. Protein-DNA complexes were resolved by electrophoresis on 4% 
polyacrylamide Tris/Borate/EDTA (TBE) gel in the dark. Quantitative data was obtained 
using computerized densitometer and TINA software [version 2.07d (Raytest)].
RNA in-situ hybridization
RNA in-situ hybridization was performed using the RNAscope 2.0 kit (Advanced Cell 
Diagnostics) according to manufacturer instructions. Briefly, 4 μm FFPE sections were 
deparaffinized in xylene and pretreated to allow access of probe to target RNA. LTβ specific 
probe pairs (Advanced Cell Diagnostics) were hybridized to the target RNA at 40°C in a 
moist hybridization oven for 2 hours. The signal was amplified using AP-conjugated labeled 
probes, followed by colorimetric detection using Fast Red as substrate. LTβ mRNA was 
visualized using standard bright-field microscopy.
Array-based Comparative Genomic Hybridization (aCGH)
Agilent oligonucleotide array based CGH for genomic DNA analysis of FFPE samples 
(Mouse Genome CGH Microarray 4x44K) was performed on genomic DNA extracted from 
FFPE liver tissues, according to the protocol provided by Agilent Technologies. Briefly, 500 
ng of liver genomic DNA was differentially labeled with Cy3-dCTP (HCC) and Cy5-dCTP 
(liver tissue from C57BL/6 mice) by random primed labeling (CGH labeling kit for oligo 
array, Enzo Life Sciences). Liver genomic DNA from C57BL/6 mice was pooled and used 
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as reference DNA. After scanning the array slides, spot fluorescence intensities were 
extracted using the Feature Extraction Software (Agilent Technologies), and the raw data 
text files were used for further analysis. The data were imported into the R statistical 
platform (http//:www.R-project.org/) and data quality outliers were filtered out using the 
quality flags as implemented in the Feature Extraction software, such as statistical 
population outliers or spots with foreground to background ratios smaller than 3. The log2 
ratios of each sample were collated into one matrix and preprocessed and analyzed as 
follows, using functions from the Bioconductor R package CGHcall46. Missing values were 
replaced using the values from neighboring probes by an imputation algorithm whereas 
probes with missing values in more than 30% of samples were excluded from the dataset. 
The remaining data were median normalized followed by breakpoint detection using a 
segmentation algorithm47, and the copy number status (loss, normal and gain) of each 
segment was determined using the CGHcall function46. The copy number calls of the single 
probes were transformed into copy number regions using the CGH regions package48 and 
plotted for each chromosome according to their physical position.
Proliferation/differentiation analysis of Figure 3e
The experimental group and tumor histology is indicated by the color code above each 
column. Clusters were determined by an unsupervised algorithm and designated A, B, the 
latter further subdivided into B1 and B2. Note that DEN induced HCCs from WT mice are 
more similar to WT liver parenchyma than IKKβ(EE)Hep, most of which fall into cluster B 
together with the aggressive Myc-TP53−/− mice. Statistical analyses of tumor types in the 
different clusters: DEN WD-HCCs vs. all IKK HCCs (cluster A vs. B) p<0.0001; DEN 
classic vs. IKK DEN tumors (both WD and HCC-CCC tumors) (A vs. B) p=0.001; DEN 
WD-HCCs vs. IKK spontaneous (spon) HCCs (both WD-HCCs and HCC-CCC tumors) (A 
vs. B) p=0.04; DEN WD-HCCs -IKK HCC-CCC (A vs. B) p=0.006; IKK WD-HCCs vs. 
IKK HCC-CCC (B1 vs. B2) p=0.007. All p values were determined by two tailed chi-square 
test. Key: WT liver (purple)= parenchymal liver tissue from untreated 6 months old Alb-cre 
mice; DEN WD-HCC (green)= well differentiated HCCs from 9 months-old DEN-treated-
Alb-cre mice; IKK spon. WD-HCC (blue)= well differentiated HCCs from 20 months-old 
IKKβ(EE)Hep mice; IKK spon. HCC-CCC (light brown)= undifferentiated mixed HCC-
CCCs from 20 months-old IKKβ(EE)Hep mice; IKK DEN WD-HCC (yellow)= well 
differentiated HCCs from 9 months-old DEN-treated-IKKβ(EE)Hep mice; IKK DEN HCC-
CCC (red)= undifferentiated mixed HCC-CCC from 9 months-old DEN-treated-
IKKβ(EE)Hep mice; Myc-TP53−/− (brown): HCCs from the very aggressive mouse model for 
HCC, Myc-TP53−/− mice. See Supplementary Table 7 for primers sequence.
FACS and cell sorter
ELSs were dissected under binocular from IKKβ(EE)Hep livers and digested for 30 minutes 
in 500μl digestion buffer (HBSS with 0.2 mg/ml collagenase IV and 0.1 mg/ml DNase1) at 
37°C with gentle agitation. The cells were strained through 40μm filter by washing with cold 
DMEM, centrifuged for 15 minutes, RBCs were lysed for 10 minutes at 25° with 
erythrocytes lysis buffer, washed again and resuspended in 0.5ml DMEM and kept on ice for 
a few hours until staining. Viability of isolated immune cells was around 85% as determined 
by Trypan blue. Cells were resuspended and stained in PBS supplemented with 1% fetal calf 
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serum and 1mM EDTA. Samples were stained and then analyzed by flow cytometry using a 
Gallios and Kaluza software (Beckman Coulter), or by fluorescence-activated cell sorter 
(FACS). Antibodies used for flow cytometry and FACS analysis: CD4 (clone RM-4.5, 
catalog#: 100536, BioLegend), CD8 (clone 53-6.7, catalog#: 65-0081 and 75-008, Tonbo), 
F4/80 (clone BM8, catalog#: 123127, BioLegend), CD11b (clone M1/70, catalog#: 101224, 
BioLegend), MHCII (clone KH74, catalog#: 115303, BioLegend), CD45.2 (clone 104, 
catalog#: 109807, BioLegend), NK1.1 (clone PK136, catalog#: 12-5941-83, eBioscience), 
TCRβ (clone: H57-597, catalog#: 35-5961, Tonbo), CD44 (clone IM7, catalog#: 103127, 
BioLegend), CD62L (clone MEL-14, catalog#: 104417, BioLegend), B220 (Catalog#: 
553090, BD Pharmingen).
Quantitative PCR analysis
Total RNA was extracted with Trizol (Invitrogen) and was reverse-transcribed by the high–
capacity cDNA reverse transcription kit (Applied Biosystems). qPCR reactions were ran in 
triplicates in 384-well plates, and were carried out with SYBR green (Invitrogen) in 7900HT 
Fast Real-Time PCR System (Applied BioSystems). Results were analyzed using either the 
Dataassist 2.0 or qBase v1.3.5 softwares. HPRT and PPIA were used as reference genes in 
both human and murine analyses. Primer sequences are available in Supplementary Tables 3, 
6 and 7 and expression fold and p-values in Supplementary Tables 2, 4 and 5.
Digital PCR analysis
Genomic DNA was extracted from fresh frozen tissue with DNeasy (QIAGEN, Catalog# 
69504) and from FFPE tissue with QIAamp DNA Micro Kit (QIAGEN, Catalog# 56304) 
and used for digital PCR analysis with the following TAQMAN probes: Rgs2, Gab2 
(Applied Biosystems, catalog# AB-4400291), Tert (Applied Biosystems, catalog# 
AB-4458368). High-throughput droplet digital PCR for quantitation of DNA copy number 
was done as described49.
Statistical analysis
Results are expressed as mean ± SEM. Statistical significance (p<0.05) was determined by 
either two-tailed Student’s t-test, two tailed chi-square test or Fisher’s exact test. For 
correlation analysis in mRNA expression levels, either Spearman or Pearson correlation tests 
at p<0.05 were used. Data was processed using Microsoft Excel or GraphPad Prism 6.0.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Hepatic ELSs signify a poor prognosis in human HCC and are associated with NF-κB 
activation
(a) Upper panel, histological ELS score: For each human sample (n=82) the percentage of 
portal areas with ELS features (green) and the type of ELS was evaluated histologically 
(black and grey colors indicate presence and absence of histological ELS, respectively; 
Agg= Aggregate, Fol=Follicle, GC=Germinal Center). Gaps indicate lack of H&E-stained 
slides. Lower panel, ELS gene signature: Heatmap for expression of each of the 12 genes 
composing the ELS gene signature6. Presence of high ELS gene signature is shown in the 
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black color bar above the gene expression heatmap. Presence of high ELS gene signature 
was determined by coherent overexpression of the signature genes with statistical 
significance (prediction confidence p<0.05), as described in the Methods (black – present, 
grey – absent; upper horizontal bar). Cases in upper and lower panels are ordered according 
to ELS gene signature. (b,c) Kaplan Meier curves for survival (b) or late recurrence (c) after 
resection of HCC, in patients with high (red) and low (blue) ELS gene signatures in the liver 
parenchyma [n=82 patients (15 high score, 67 low score); *p=0.01 and 0.03 for (b) and (c), 
respectively, Log-rank test]. (d,e) Hazard ratios of the ELS gene signature for overall 
survival (d) and late recurrence (e) in multivariable Cox regression modeling adjusted for 
186-gene prognostic HCC risk13 and American Association for Study of Liver Diseases 
(AASLD) prognostic stage40. Bars - 95% confidence interval. (f) Heatmap for NF-κB 
signature enrichment in the same cohort of human patients as in (a). NF-κB signature 
enrichment was determined by modulation of 3 experimentally defined sets in HeLa cells, 
primary human fibroblasts and keratinocytes (see Methods for details). In all 3 panels, 
samples are ordered according to the extent of ELS signature induction from left to right 
(same order as in a).
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Figure 2. Persistent liver IKK activation induces ectopic lymphoid structures
(a) Immunoblot analysis for Flag-tagged IKKβ(EE) in tissues of Alb-cre control and 
IKKβ(EE)Hep mice. Tubulin - loading control (shown two representative mice per group). 
(b,c) Quantification of ELS number and size in IKKβ(EE)Hep livers. Control Alb-cre mice 
do not develop follicles (n=10,8,6,5 for control, 4,7 and 14 months old IKKβ(EE)Hep mice, 
respectively; *p=0.0002, **p=0.00001, two-tailed Students t-test, red line signifies mean). 
(d) Representative H&E and immunostained sections of IKKβ(EE)Hep mouse and human 
livers from patients with chronic hepatitis showing presence of immune follicles (scale bars 
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50 μm, FDCs, follicular dendritic cells, HEVs, high endothelial venules). (e) Cells from 
microscopically isolated ELSs from IKKβ(EE)Hep mice livers were analyzed by flow 
cytometry for markers indicative of the shown cell types (red line signifies mean, results are 
representative of ELSs isolated from at least 6 IKKβ(EE)Hep mice). Data arerepresentative of 
three independent experiments in (a) and (d) and of one experiment in (e).
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Figure 3. Persistent activation of IKK in hepatocytes induces aggressive HCC
(a,b) Tumor number (≥0.5 cm) and volume in livers of 20-month-old Alb-cre control and 
IKKβ(EE)Hep mice (n=13,11 for control and IKKβ(EE)Hep, respectively; *p≤0.0002, two-
tailed Students t-test, red line signifies mean). (c) Representative livers and H&E stained 
sections from 20-month-old Alb-cre and IKKβ(EE)Hep mice. Arrows indicate tumors (scale 
bar- 200 μm). (d) Representative H&E stains of HCCs from 20-month old IKKβ(EE)Hep 
mice. WD-HCC= well-differentiated HCC, CCC= cholangiocellular carcinoma (scale bar- 
100 μm). (e) Heat map representation of relative mRNA expression of a 16-gene HCC 
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proliferation and differentiation signature20 in wild-type (WT) liver parenchyma or HCCs 
derived from the indicated mice (for further details see Methods). Clusters were determined 
by an unsupervised algorithm and designated A, B, the latter further subdivided into B1 and 
B2. Note that DEN induced HCCs from WT mice are more similar to WT liver parenchyma 
than IKKβ(EE)Hep, most of which fall into cluster B together with the aggressive HCCs of 
Myc-TP53−/− mice. Statistical analyses of tumor types in the different clusters: DEN WD-
HCCs vs. all IKK HCCs (cluster A vs. B) p=6.0E-05; DEN WD vs. IKK DEN tumors (both 
WD and HCC-CCC tumors) (A vs. B) p=0.001; DEN WD-HCCs vs. IKK spontaneous 
(spon) HCCs (both WD-HCCs and HCC-CCC tumors) (A vs. B) p=0.04; DEN WD-HCCs -
IKK HCC-CCC (A vs. B) p=0.006; IKK WD-HCCs vs. IKK HCC-CCC (B1 vs. B2) 
p=0.007. n=4,7,8,8,3 for WT, DEN treated Alb-cre, DEN treated IKKβ(EE)Hep, untreated 
IKKβ(EE)Hep and Myc-TP53−/− mice, respectively; All p values were determined by two 
tailed chi-square test. Data arerepresentative of two independent experiments in (a) and (b) 
and of one experiment in (e).
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Figure 4. HCC progenitors appear in ELSs and progressively egress out
a) Representative co-immunofluoresence stains for GFP (green) expressed from the 
hepatocyte specific IKKβ(EE) transgene and the epithelial marker E-cadherin (red) depicting 
the epithelial origin of HCC progenitors. Hoechst 33342 (blue) marks the nuclei (scale bars 
100 μm). (b) Representative immunostains for indicated HCC progenitor markers in ELSs of 
IKKβ(EE)Hep mice (scale bars 50 μm). (c) Representative H&E stained sections of 
IKKβ(EE)Hep livers depicting ELS to HCC progression (arrow points to small ELS; scale 
bars 50 μm). (d) Representative 3-dimensional (3D) reconstruction of an ELS from a 6 
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month old DEN-treated IKKβ(EE)Hep mouse. Left upper panel: double color 
immunostaining for CD44v6 (brown) and B220 (red). Right upper panel: color conversion 
of the left panel (brown to green, red to purple). Lower panels: Two different rotations of a 
3D reconstruction. Note green CD44v6+ progenitor cells egressing out of the ELS at 
multiple points (scale bars 100 μm). α, β and γ show the same region in all panels. See also 
Supplementary video 1. (e) Representative immunostains of two different livers (#1 and #2) 
from 14 month old untreated IKKβ(EE)Hep mice and 6 month old DEN treated IKKβ(EE)Hep 
mice for the pericentral marker glutamine synthetase (GS). Red and blue arrows indicate 
periportal and pericentral ELSs, respectively. Brown staining highlights pericentral zones 
(scale bars 100 μm). (f) Representative confocal microscopy images of ELS-containing liver 
sections from a human patient for the HCC progenitor markers HSP70 (green) and Sox9 
(purple) and for the bile duct marker CK19 (red). DAPI (blue) marks the nuclei. Arrow 
points to a group of HCC progenitors (scale bars 100 μm, arrow points to progenitor cell). 
Data are representative of three independent experiments in (a) and (b), and of one 
experiment in (d), (e) and (f).
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Figure 5. Adaptive immune cells are required for ELS-dependent HCC promotion
(a,b) Tumor numbers (≥3 mm and ≥5 mm, respectively) and volume (c) in livers of 6 month 
old DEN-treated Alb-cre control, Rag1−/−, IKKβ(EE)Hep and IKKβ(EE)Hep -Rag1−/− (IKK-
Rag) mice (n=11,10,12,12 for control, Rag1−/−, IKKβ(EE)Hep and IKK-Rag, respectively; 
*p≤0.006, two-tailed Students t-test; red line signifies mean). (d) Representative images of 
livers from 6-month-old DEN-treated mice. Arrows indicate tumors. (e,f) Tumor 
quantification by classification to well differentiated HCC (WD-HCC) or mixed cholangio-
hepatocellular carcinoma (HCC-CCC). n=11 for each group; *p≤0.00004, two-tailed 
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Students t-test; red line signifies mean. (g) Representative immunostains for the HCC 
progenitor markers A6, CD44v6, CK19 and Sox9 in 6 month old DEN-treated livers. HCC 
progenitors in IKKβ(EE)Hep liver are within ELSs, whereas the rare ones occasionally seen 
in IKKβ(EE)Hep -Rag1−/− mice are in the parenchyma (scale bars- 50 μm). Data are 
representative of one experiment, n=8.
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Figure 6. Anti-Thy1.2 immuno-ablative treatment during ELS development attenuates liver 
tumorigenesis
(a) Representative images of immunostaining for CD3 in livers from control or anti-Thy1.2 
injected 6 months old DEN-treated IKKβ(EE)Hep mice (n=6, scale bars upper 200 μm, lower 
50 μm). (b) Mice were treated with control or anti Thy1.2 antibody. Representative sections 
from the entire liver were assessed for the total number of ELSs and presence of ELSs of 
various sizes as indicated (n=6,5 for control or anti-Thy1.2, respectively; *p≤0.04, 
**p≤0.003, red line signifies mean) (c) Representative images of livers from control or anti-
Thy1.2 injected 6-months-old DEN-treated IKKβ(EE)Hep mice. n=6,10 for control and anti-
Thy1.2, respectively; arrows indicate tumors. (d,e) Tumor number (≥3 mm) (d) and volume 
(e) in livers of control or anti-Thy1.2 injected 6-month-old DEN-treated IKKβ(EE)Hep mice 
(n=6,10 for control and anti-Thy1.2, respectively; *p≤0.04, two-tailed Students t-test, red 
line signifies mean). Data are representative of one experiment.
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Figure 7. ELS microniches provide a rich cytokine milieu
(a) mRNA qPCR analysis of liver parenchyma and HCCs from IKKβ(EE)Hep or DEN-
treated IKKβ(EE)Hep mice (M=months of age), as well as in liver parenchyma of 3 month 
old IKKβ(EE)Hep mice without DEN treatment. Each data point reflects the median 
expression, normalized to the mean expression of the same gene in control livers derived 
from the equivalent Alb-cre control mice (for further details see Supplementary Tables 3, 4 
& 5). (b) Heat map (upper) and scatter plot (lower) representations of mRNA qPCR analyses 
of liver tissue from HCV-infected patients (n=43) relative to healthy controls (n=12). Scatter 
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plots depict mRNA amounts of LTβ, CCL17 and CCL20 (for further details see 
Supplementary Tables 5 & 6; *p<0.0001, two-tailed Students t-test, Log10 scale, cross line 
signifies mean). (c) Representative immunostaining for LTβ in HCV-infected human liver 
(scale bars: upper 200 μm; lower 50 μm). (d) Representative LTβ-mRNA in situ 
hybridization in mouse livers (scale bars 50 μm). (e) Quantification of LTβ expression in 
malignant hepatocytes. The % of LTβ positive hepatocytes was determined by counting 10 
ELSs from each mouse (n=8,5,6,5 for control, 3, 6 and 9 months old mice, respectively; 
*p=0.0003, **p=0.00006, two-tailed Students t-test, red line signifies mean). (f) 
Representative serial sections showing LTβ mRNA in-situ hybridization and immunostaining 
for the progenitor marker A6. Note LTβ staining of immune cells and egressing hepatocytes 
(black arrows) but not niche residing ones (white arrows, scale bars-100 μm). (g) 
Representative images of LTβ-mRNA in-situ hybridization in hepatic ELSs of control or 
anti-Thy1.2 injected 6 month old DEN-treated IKKβ(EE)Hep mice (scale bars-50 μm). (h) 
qPCR analysis of LTβ mRNA expression in liver parenchyma of control or anti-Thy1.2 
injected 6 month old DEN-treated IKKβ(EE)Hep mice (n=10,6 respectively; *p=0.003 two-
tailed Students t-test, red line signifies mean). Data are representative of one experiment in 
(a) and (b) and of two independent experiments in (c), (d), (f) and (g).
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Figure 8. Blocking LT signaling abolishes microniche egression and tumorigenesis
(a) Heat map representation of mRNA qPCR analysis of liver parenchyma from 33-weeks-
old IKKβ(EE)Hep mice treated with LTβR-Ig for 10 consecutive weeks (23-32 weeks, see 
Supplementary Fig. 8a). Each data point reflects the median expression, normalized to the 
mean expression of the same gene in equivalent control murine-IgG1-injected IKKβ(EE)Hep 
mice (Log2 scale; See Supplementary Tables 4 & 5). (b) Tumor number (≥0.5 cm) in livers 
of 33 week old IKKβ(EE)Hep mice treated with either control-Ig or LTβR-Ig for the 
indicated periods (n=12,11,10,11 for control, 3-12w, 13-22w or 23-32w, respectively; 
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*p=0.04, **p=0.0002, two-tailed Students t-test, red line signifies mean). (c,d) 
Quantification of the percent of ELSs showing egressed progenitor hepatocytes (c) and of 
the number of egressing hepatocyte clusters per ELS (d) [n=7,11 for control-Ig and LTβR-Ig 
treated mice, respectively; *p=0.02, and 0.00009 for (c) and (d), respectively; two-tailed 
Students t-test, red line signifies mean]. (e) Quantification of the CDC47+Sox9+ double 
positive cells in ELSs (see below, pink in g, right panels) (n=6; *p=0.02, two-tailed Students 
t-test, red line signifies mean). (f) Quantification of the GFP+ cells inside the ELSs (n=6; 
*p=0.001, two-tailed Students t-test, red line signifies mean). (g) Representative confocal 
microscopy images of ELS-containing liver sections from DEN-treated IKKβ(EE)Hep mice 
injected for 10 consecutive weeks (23-32 weeks) with control-Ig or LTβR-Ig for GFP, 
CDC47 and Sox9. Hoechst 33342 marks the nuclei. Arrows indicate CDC47+Sox9+ double 
positive cells in pink (scale bars 100 μm). Data are representative of one experiment in (a) 
and (b) and of two independent experiments in (g).
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